GlassScriptPhysician profile
General L Cranfill
NPI 1093726333
$2,198.86
in general payments reported to CMS, 2019-2025
26 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $635 · 2023: $681 · 2024: $447 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $473.61 | 2022-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Amgen INC. | $395.06 | 2022-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $279.71 | 2022-2025 | |
| Abbvie INC. | $242.00 | 2023-2025 | Vraylar, Ubrelvy, Dalvance |
| Astrazeneca Pharmaceuticals LP | $106.17 | 2022-2025 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.35 | 2022-2024 | Xifaxan |
| Astellas Pharma US INC | $82.22 | 2022-2023 | Myrbetriq, Veozah |
| Lilly USA, LLC | $68.77 | 2022-2023 | Jardiance, Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $52.60 | 2022 | |
| Daiichi Sankyo INC. | $45.93 | 2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $41.72 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $38.02 | 2022-2023 | Verquvo, Belsomra |
| Edwards Lifesciences Corporation | $31.04 | 2025 | Sapien 3 Ultra Resilia |
| Inspire Medical Systems, INC. | $28.77 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $26.64 | 2023 | Quviviq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.47 | 2023 | Glassia |
| Xeris Pharmaceuticals, INC. | $21.36 | 2022 | |
| Genentech USA, INC. | $20.52 | 2024 | Itovebi, Hemlibra, Alecensa |
| Teva Pharmaceuticals USA, INC. | $18.72 | 2022 | |
| Corium, LLC | $18.62 | 2023 | Adlarity |
| Nestle Healthcare Nutrition INC. | $17.31 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.97 | 2023 | Ofev |
| Currax Pharmaceuticals LLC | $13.57 | 2023 | Contrave, Onzetra Xsail |
| Boston Scientific Corporation | $13.38 | 2023 | Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $13.29 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw General Cranfill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.